New Mountain Capital’s Continuation Fund
New Mountain Capital has disclosed details of its latest continuation vehicle (CV), offering LPs various roll or sell options in a $3 billion deal for health innovation company Real Chemistry. LPs in Fund V can sell their stakes for immediate liquidity, roll their interests into the CV, or upsize their commitments. The CV, led by Coller Capital with Goldman Sachs as an advisor, will include the main Real Chemistry unit and its spinoff, Swoop. New Mountain is also developing an internal secondaries strategy focused on GP-led continuation fund deals.